Management of osteoporosis in postmenopausal women: 2010 position statement of The North American

Menopause Society. Menopause. 2010;17(1):25–54. doi:10.1097/gme.0b013e3181c617e6. (32)

McCloskey E. FRAX

® Identifying People at High Risk of Fracture WHO Fracture Risk Assessment Tool, a New

Clinical Tool for Informed Treatment Decisions. International Osteoporosis Foundation (IOF); 2009.

https://www.iofbonehealth.org/sites/default/files/PDFs/WOD%20Reports/FRAX_report_09.pdf. (44)

National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington,

DC: National Osteoporosis Foundation; 2013. (1)

Schousboe JT et al. Executive summary of the 2013 ISCD position development conference on bone densitometry.

JCD. 2013;4:455–467. (43)

Siris ES et al. The clinical diagnosis of osteoporosis: a position statement from the national bone health alliance

working group. Osteoporos Int. 2014;25(5):1439–1443. (2)

The International Society for Clinical Densitometry (ISCD): http://www.iscd.org.

Watts NB et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab.

2012;97(6):1802–1822. doi:10.1210/jc.2011-3045. (24)

Key Websites

Institute for Clinical Systems Improvement (ICSI) Osteoporosis, Diagnosis and Treatment:

https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_musculoskeleInternational Osteoporosis Foundation: http://www.iofbonehealth.org/.

National Osteoporosis Foundation: NOF.org.

COMPLETE REFERENCES CHAPTER 110 OSTEOPOROSIS

National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington,

DC: National Osteoporosis Foundation; 2013.

Siris ES et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance

Working Group. Osteoporos Int. 2014;25(5):1439–1443.

South-PaulJE. Osteoporosis: part I. Evaluation and assessment. Am Fam Physician. 2001;63(5):897–904, 908.

Finkelstein JS et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of

women. J Clin Endocrinol Metab. 2008;93(3):861–868.

Emkey GR, Epstein S. Secondary osteoporosis: pathophysiology & diagnosis. Best Pract Res Clin Endocrinol

Metab. 2014;28(6):911–935. doi:10.1016/j.beem.2014.07.002.

Kanis JA et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–1141.

doi:10.1002/jbmr.5650090802.

Kanis J on behalf of the WHOSG (2007). Assessment of Osteoporosis at the Primary Health-Care Level.

Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of

Sheffield, UK; 2007. Printed by the University of Sheffield.

Osteoporosis/Bone Health in Adults as a National Public Health Priority. Position Statement 1113. American

Academy of Orthopaedic Surgeons (AAOS); 2014. https://www.aaos.org/About/Statements/Position/?

ssopc=1.

Cauley JA. Defining ethnic and racial differences in osteoporosis and fragility fractures. Clin Orthop.

2011;469(7):1891–1899. doi:10.1007/s11999-011-1863-5.

Looker A et al. Osteoporosis or Low Bone Mass at the Femur Neck or Lumbar Spine in Older Adults: United

States, 2005–2008. NCHS Data Brief No 93. Hyattsville, MD: National Center for Health Statistics; 2012.

Wright NC et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone

mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–2526.

doi:10.1002/jbmr.2269.

Becker DJ et al. The societal burden of osteoporosis. Curr Rheumatol Rep. 2010;12(3):186–191.

doi:10.1007/s11926-010-0097-y.

Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008;3(Suppl 3):S131–S139.

doi:10.2215/CJN.04151206.

Riggs BL, Melton LJ. Involutional osteoporosis. N Engl J Med. 1986;314(26):1676–1686.

doi:10.1056/NEJM198606263142605.

Kini U, Nandeesh B. Physiology of bone formation, remodeling, and metabolism. In: Fogelman I et al, eds.

Radionuclide and Hybrid Bone Imaging. Heidelberg: Springer; 2012.

Riggs BL, Khosla S, Melton LJ. A unitary model for involutional osteoporosis: estrogen deficiency causes both

type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone

Miner Res. 1998;13(5):763–773. doi:10.1359/jbmr.1998.13.5.763.

Khosla S et al. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision

needed? J Bone Miner Res. 2011;26(3):441–451. doi:10.1002/jbmr.262.

Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North

Am. 2005;34(4):1015–1030. doi:10.1016/j.ecl.2005.07.009.

Vandenput L et al. Serum estradiol levels are inversely associated with cortical porosity in older men. J Clin

Endocrinol Metab. 2014;99(7):E1322–E1326. doi:10.1210/jc.2014-1319.

Khosla S, et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus

elderly men. J Clin Endocrinol Metab. 2001;86(8):3555–3561. doi:10.1210/jcem.86.8.7736.

Nicks KM, Fowler TW, Gaddy D. Reproductive Hormones and Bone. Curr Osteoporos Rep. 2010;8(2):60-67.

doi:10.1007/s11914-010-0014-3.

U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon

General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General;

2004.

Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep. 2009;7(1):18–22.

Watts NB et al. Osteoporosis in men: an endocrine society clinical practice guideline. J Clin Endocrinol Metab.

2012;97(6):1802–1822. doi:10.1210/jc.2011-3045.

Dawson-Hughes B et al. The potential impact of the National Osteoporosis Foundation guidance on treatment

eligibility in the USA: an update in NHANES 2005–2008. Osteoporos Int. 2012;23(3):811–820.

doi:10.1007/s00198-011-1694-y.

Florence R et al. Institute for Clinical Systems Improvement. Diagnosis and Treatment of Osteoporosis. Updated

July 2013.

De Laet C et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int J.

2005;16(11):1330–1338. doi:10.1007/s00198-005-1863-y.

Syed FA, Ng AC. The pathophysiology of the aging skeleton. Curr Osteoporos Rep. 2010;8(4):235–240.

doi:10.1007/s11914-010-0035-y.

Marini F, Brandi ML. Genetic determinants of osteoporosis: common bases to cardiovascular diseases? Int J

Hypertens. 2010;2010. doi:10.4061/2010/394579.

Klein RF, Foroud T. Chapter 1 Human and Animal Studies of the Genetics of Osteoporosis. In: Orwoll ES,

Bliziotes, eds. Osteoporosis Pathophysiology and Clinical Management. Totowa, NJ: Humana Press; 2003.

Howe TE et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database

Syst Rev. 2011;(7):CD000333. doi:10.1002/14651858.CD000333.pub2.

Management of osteoporosis in postmenopausal women: 2010 position statement of The North American

Menopause Society. Menopause. 2010;17(1):25–54. doi:10.1097/gme.0b013e3181c617e6.

Ross AC et al, eds. Institute of Medicine Committee to Review Dietary Reference Intakes for Calcium and

Vitamin D. Washington, DC: National Academies Press; 2011.

Nutrient Recommendations: Dietary Reference Intakes (DRI). National Institutes of Health Office of Dietary

Supplements. http://ods.od.nih.gov/Health_Information/Dietary_Reference_Intakes.aspx. Accessed

May 26, 2015.

Avenell A et al. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and

older men. Cochrane Database Syst Rev. 2014;(4):CD000227. doi:10.1002/14651858.CD000227.pub4.

Newberry SJ et al. Vitamin D and calcium: a systematic review of health outcomes (update). Evid Rep Technol

Assess No 217.

Dietary Supplement Fact Sheets. http://ods.od.nih.gov/factsheets/list-all/. Accessed May 26, 2015.

Orchard TS et al. Magnesium intake, bone mineral density, and fractures: results from the women’s health

initiative observationalstudy. Am J Clin Nutr. 2014;99(4):926–933. doi:10.3945/ajcn.113.067488.

Falcone TD et al. Vitamin K: fracture prevention and beyond. PM R. 2011;3(6):S82–S87.

Iwamoto J. Vitamin K therapy for postmenopausal osteoporosis. Nutrients. 2014;6(5):1971–1980.

doi:10.3390/nu6051971.

Booth SL et al. Effect of vitamin K supplementation on bone loss in elderly men and women. J Clin Endocrinol

Metab. 2008;93(4):1217–1223. doi:10.1210/jc.2007-2490.

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO

Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.

Schousboe JT et al. Executive summary of the 2013 ISCD position development conference on bone

densitometry. JCD. 2013;4:455–467.

McCloskey E. FRAX® Identifying People at High Risk of Fracture WHO Fracture Risk Assessment Tool, a

New Clinical Tool for Informed Treatment Decisions. International Osteoporosis Foundation (IOF); 2009.

https://www.iofbonehealth.org/sites/default/files/PDFs/WOD%20Reports/FRAX_report_09.pdf.

Cosman F et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–

2381. doi:10.1007/s00198-014-2794-2.

Ettinger B, Grady D. The waning effect of postmenopausal estrogen therapy on osteoporosis. N Engl J Med.

1993;329(16):1192–1193. doi:10.1056/NEJM199310143291610.

Siris ES et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal

women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286(22):2815–2822.

Banks E et al; Million Women Study Collaborators. Fracture incidence in relation to the pattern of use of hormone

therapy in postmenopausal women. JAMA. 2004;291(18):2212–2220. doi:10.1001/jama.291.18.2212.

Cauley JA. The women’s health initiative: hormone therapy and calcium/vitamin d supplementation trials. Curr

Osteoporos Rep. 2013;11(3):171–178. doi:10.1007/s11914-013-0150-7.

Manson JE et al. Menopausal hormone therapy and health outcomes during the intervention and extended

poststopping phases of the women’s health initiative randomized trials. JAMA. 2013;310(13):1353.

doi:10.1001/jama.2013.278040.

Grady D et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline

characteristics. Control Clin Trials. 1998;19(4):314–335.

Grady D et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and

Estrogen/progestin Replacement Study follow-up (HERS II) [published correction appears in JAMA.

2002;288:1064]. JAMA. 2002;288(1):49–57.

Cauley JA et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the women’s

health initiative randomized trial. JAMA. 2003;290(13):1729–1738. doi:10.1001/jama.290.13.1729.

PREMPRO (conjugated Estrogens/medroxyprogesterone Acetate Tablets) PREMPHASE (conjugated Estrogens

plus Medroxyprogesterone Acetate Tablets). Philadelphia, PA: Wyeth Pharmaceuticals Inc., a subsidiary of

Pfizer Inc.; 2015.

Bisphosphonate: Summary of Indications. Drug Facts and Comparisons. Facts & Comparisons [database Online].

St. Louis, MO: Wolters Kluwer Health, Inc; 2011. http://online.factsandcomparisons.com. Accessed June

18, 2015.

Naylor KE et al. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal

osteoporosis: the TRIO study. Osteoporos Int. 2016;27:21–31. doi:10.1007/s00198-015-3145-7.

Wells GA et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in

postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD001155.

doi:10.1002/14651858.CD001155.pub2.

Hosking D et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N

EnglJ Med. 1998;338(8):485–492. doi:10.1056/NEJM199802193380801.

McClung MR et al. Oral Daily ibandronate prevents bone loss in early postmenopausal women without

osteoporosis. J Bone Miner Res. 2004;19(1):11–18. doi:10.1359/JBMR.0301202.

Reginster J-Y. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year

results from the mobile study. Ann Rheum Dis. 2006;65(5):654–661. doi:10.1136/ard.2005.044958.

Miller PD, Recker RR, Reginster J-Y, et al. Efficacy of monthly oral ibandronate is sustained over 5 years: the

MOBILE long-term extension study. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl

Osteoporos Found USA. 2012;23(6):1747–1756. doi:10.1007/s00198-011-1773-0.

Delmas PD et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year

results from the dosing intravenous administration study. Arthritis Rheum. 2006;54(6):1838–1846.

doi:10.1002/art.21918.

Mortensen L et al. Risedronate increases bone mass in an early postmenopausal population: two years of

treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998;83(2):396–402.

doi:10.1210/jcem.83.2.4586.

Delmas PD et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety

results. Osteoporos Int. 2008;19(7):1039–1045. doi:10.1007/s00198-007-0531-9.

McClung MR et al. A novel monthly dosing regimen of risedronate for the treatment of postmenopausal

osteoporosis: 2-year data. Calcif Tissue Int. 2013;92(1):59–67. doi:10.1007/s00223-012-9668-4.

Delmas PD et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal

osteoporosis. Bone. 2008;42(1):36–42. doi:10.1016/j.bone.2007.09.001.

McClung M et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass:

a randomized controlled trial. Obstet Gynecol. 2009;114(5):999–1007. doi:10.1097/AOG.0b013e3181bdce0a.

Diab DL, Watts NB. Use of drug holidays in women taking bisphosphonates: Menopause. 2014;21(2):195–197.

doi:10.1097/GME.0b013e31829ef343.

Rodan G et al. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin. 2004;20(8):1291–1300.

doi:10.1185/030079904125004475.

Black DM et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention

trial long-term extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927. doi:10.1001/jama.296.24.2927.

McClung MR et al. Prevention of postmenopausal bone loss: six-year results from the early postmenopausal

intervention cohort study. J Clin Endocrinol Metab. 2004;89(10):4879–4885. doi:10.1210/jc.2003-031672.

Black DM et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second

extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30(5):934–944.

doi:10.1002/jbmr.2442.

Durchschlag E et al. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-

year treatment with risedronate. J Bone Miner Res. 2006;21(10):1581–1590. doi:10.1359/jbmr.060701.

Diab DL, Watts NB. Bisphosphonate drug holiday: who, when and how long. Ther Adv Musculoskelet Dis.

2013;5(3):107–111. doi:10.1177/1759720X13477714.

Fosamax (Alendronate) [Package Insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2013.

Actonel (Risedronate) [Package Insert]. Mason, OH: Warner Chilcott Pharmaceuticals Inc.; 2015.

Drug Safety and Availability > Medication Guides. http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm.

Accessed June 4, 2015.

Reclastl (Zoledronic Acid) [Package Insert]. East Hanover, New Jersey: Novartis Pharmaceutical Corporation;

2015.

Drug Safety Information for Heathcare Professionals > Update of Safety Review Follow-up to the October 1,

2007 Early Communication about the Ongoing Safety Review of Bisphosphonates.

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInfoPublished November 12, 2008. Accessed June 15, 2015.

Drug Safety Podcasts > Podcast for Healthcare Professionals: Ongoing Safety Review of Oral Bisphosphonates

and Atypical Subtrochanteric Femur Fractures.

.

.

.

.

.

http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm204950.htm. Accessed June 15, 2015.

Lee S et al. Increased risk for atypical fractures associated with bisphosphonate use. Fam Pract. 2015;32(3):276–

281. doi:10.1093/fampra/cmu088.

Park-Wyllie LY et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older

women. JAMA. 2011;305(8):783–789. doi:10.1001/jama.2011.190.

Drug Facts and Comparisons. Facts & Comparisons [Database Online]. St. Louis, MO: Wolters Kluwer Health,

Inc; 2011. http://online.factsandcomparisons.com. Accessed June 18, 2015.

Martinkovich S et al. Selective estrogen receptor modulators: tissue specificity and clinical utility. Clin Interv

Aging. 2014;9:1437–1452. doi:10.2147/CIA.S66690.

Messalli EM, Scaffa C. Long-term safety and efficacy of raloxifene in the prevention and treatment of

postmenopausal osteoporosis: an update. Int J Womens Health. 2010;1:11–20.

Delmas PD et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine

endometrium in postmenopausal women. N Engl J Med. 1997;337(23):1641–1647.

doi:10.1056/NEJM199712043372301.

Jolly EE et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5

years. Menopause. 2003;10(4):337–344. doi:10.1097/01.GME.0000058772.59606.2A.

Sambrook PN et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in

postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAXR versus

EVISTARComparison Trial) International1. J Intern Med. 2004;255(4):503–511. doi:10.1111/j.1365-

2796.2004.01317.x.

Evista (Raloxifene) [Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2015.

Ettinger B et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with

raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE)

Investigators. JAMA. 1999;282(7):637–645.

Riggs BL, Melton LJ. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral

fractures without commensurate increases in bone density. J Bone Miner Res. 2002;17(1):11–14.

doi:10.1359/jbmr.2002.17.1.11.

DUAVEE—Estrogens, Conjugated and Bazedoxifene Acetate Tablet, Film Coated [Package Insert] .

Philadelphia, PA: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.; 2013.

Briggs AM et al. The vertebral fracture cascade in osteoporosis: a review of aetiopathogenesis. Osteoporos Int.

2007;18(5):575–584. doi:10.1007/s00198-006-0304-x.

Oleksik AM et al. Impact of incident vertebral fractures on health related quality of life (HRQOL) in

postmenopausal women with prevalent vertebral fractures. Osteoporos Int. 2005;16(8):861–870.

doi:10.1007/s00198-004-1774-3.

Lindsay R et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285(3):320–323.

Curtis JR et al. Is withholding osteoporosis medication after fracture sometimes rational? a comparison of the risk

for second fracture versus death. J Am Med Dir Assoc. 2010;11(8):584–591. doi:10.1016/j.jamda.2009.12.004.

Hitz MF et al. Bone mineral density and bone markers in patients with a recent low-energy fracture: effect of 1

year of treatment with calcium and vitamin D. Am J Clin Nutr. 2007;86(1):251–259.

Grant AM et al. Oral Vitamin D3

and calcium for secondary prevention of low-trauma fractures in elderly people

(randomised evaluation of calcium or vitamin D, record): a randomised placebo-controlled trial. Lancet.

2005;365(9471):1621–1628. doi:10.1016/S0140-6736(05)63013-9.

Faulkner KA et al. Higher 1,25-dihydroxyvitamin D3

concentrations associated with lower fall rates in older

community-dwelling women. Osteoporos Int. 2006;17(9):1318–1328. doi:10.1007/s00198-006-0071-8.

Snijder MB et al. Vitamin D status in relation to one-year risk of recurrent falling in older men and women. J

Clin Endocrinol Metab. 2006;91(8):2980–2985. doi:10.1210/jc.2006-0510.

Salles N. Basic mechanisms of the aging gastrointestinal tract. Dig Dis. 2007;25(2):112–117.

doi:10.1159/000099474.

Straub DA. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin

Pract. 2007;22(3):286-296.

Centers for Disease Control and Prevention. Falls Among Older Adults: An Overview. Atlanta, GA: Centers for

Disease Control and Prevention National Center for Injury Prevention and Control (NCIPC); 2015.

http://www.cdc.gov/HomeandRecreationalSafety/Falls/adultfalls.html. Last updated March 19, 2015.

El-Khoury F et al. The effect of fall prevention exercise programmes on fall induced injuries in community

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

dwelling older adults: systematic review and meta-analysis of randomised controlled trials. BMJ.

2013;347():f6234. doi:10.1136/bmj.f6234.

Panel on prevention of falls in older persons, American Geriatrics Society and British Geriatrics Society.

Summary of the Updated American Geriatrics Society/British Geriatrics Society Clinical Practice Guideline for

prevention of falls in older persons. J Am Geriatr Soc. 2011;59(1):148–157. doi:10.1111/j.1532-

5415.2010.03234.x.

Ettinger B. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with

raloxifene; results from a 3-year randomized clinical trial. JAMA. 1999;282(7):637. doi:10.1001/jama.282.7.637.

Cauley JA et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-

year results from the more trial. Multiple outcomes of raloxifene evaluation. Erratum in Breast Cancer Res

Treat 2001 May;67(2):191. Breast Cancer Res Treat. 2001;65(2):125–134.

Siris ES et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to evista

(core) study. J Bone Miner Res. 2005;20(9):1514–1524. doi:10.1359/JBMR.050509.

Lin T et al. Alendronate versus raloxifene for postmenopausal women: a meta-analysis of seven head-to-head

randomized controlled trials. Int J Endocrinol. 2014;2014:1–16. doi:10.1155/2014/796510.

Crandall C et al. Treatment to prevent fractures in men and women with low bone density or osteoporosis:

update of a 2007 report. Comparative Effectiveness Review No 53 (Prepared by Southern California Evidencebased Practice Center under Contract No HHSA-290-2007-10062-I) Rockville, MD: Agency for Healthcare

Research and Quality; 2012. www.effectivehealthcare.ahrq.gov/reports/final.cfm.

Boniva (Ibandronate) [Package Insert]. South San Francisco, CA: Genentech USA, Inc.; 2015.

Wells GA et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in

postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD004523.

doi:10.1002/14651858.CD004523.pub3.

Chesnut III CH et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in

postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–1249. doi:10.1359/JBMR.040325.

Murad MH et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a

systematic review and network meta-analysis. J Clin Endocrinol Metab. 2012;97(6):1871–1880.

doi:10.1210/jc.2011-3060.

Black DM et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med.

2007;356(18):1809–1822. doi:10.1056/NEJMoa067312.

Johnson BE. A once-yearly IV infusion of zoledronic acid prevented fractures in postmenopausal women with

osteoporosis. ACP J Club. 2007;147(2):31.

Overman RA et al. Salmon calcitonin use and associated cancer risk. Ann Pharmacother. 2013;47(12):1675–

1684. doi:10.1177/1060028013509233.

Miacalcin (Calcitonin-Salmon) Injection [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals

Corporation; 2014.

Miacalcin (Calcitonin-Salmon) Nasal Spray, [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals

Corporation; 2014.

Prolia (Denosumab) Injection [Package Insert]. Thousand Oaks, CA: Amgen Inc; 2015.

Cummings SR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N

EnglJ Med. 2009;361(8):756–765. doi:10.1056/NEJMoa0809493.

Kendler DL et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72–81. doi:10.1359/jbmr.090716.

Seeman E et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab

and alendronate. J Bone Miner Res. 2010;25(8):1886–1894. doi:10.1002/jbmr.81.

Recknor C et al. Denosumab compared with ibandronate in postmenopausal women previously treated with

bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013;121(6):1291–1299.

doi:10.1097/AOG.0b013e318291718c.

Palacios S et al. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates

who transitioned to denosumab compared with risedronate or ibandronate. J Clin Endocrinol Metab.

2015;100(3):E487–E492. doi:10.1210/jc.2014-3594.

Forteo (Teriparatide [rDNA Origin] Injection) [Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2013.

Neer RM et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal

women with osteoporosis. N EnglJ Med. 2001;344(19):1434–1441. doi:10.1056/NEJM200105103441904.

Vestergaard P et al. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

mineral density and fracture risk--a meta-analysis. Osteoporos Int. 2007;18(1):45–57. doi:10.1007/s00198-006-

0204-0.

Obermayer-Pietsch BM et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal

women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res.

2008;23(10):1591–1600. doi:10.1359/jbmr.080506.

TsaiJN et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the

DATA study randomised trial. Lancet. 2013;382(9886):50–56. doi:10.1016/S0140-6736(13)60856-9.

Leder BZ et al. Two years of Denosumab and teriparatide administration in postmenopausal women with

osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab.

2014;99(5):1694–1700. doi:10.1210/jc.2013-4440.

Zhang Q et al. Parathyroid hormone plus alendronate in osteoporosis: a meta-analysis of randomized controlled

trials. Int J Clin Exp Med. 2015;8(3):3338–3348.

Cosman F et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or

raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab.

2009;94(10):3772–3780. doi:10.1210/jc.2008-2719.

Cosman F et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in

postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):503–511. doi:10.1002/jbmr.238.

Kwon Y-D et al. Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related

osteonecrosis of the jaws. Osteoporos Int. 2012;23(11):2721–2725. doi:10.1007/s00198-011-1882-9.

Neuprez A et al. Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic

patient. Calcif Tissue Int. 2014;95(1):94–96. doi:10.1007/s00223-014-9858-3.

Nakamura T et al. Randomized TERIPARATIDE [human parathyroid hormone (PTH) 1-34] Once-Weekly

Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with

primary osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012;97(9):3097–3106.

doi:10.1210/jc.2011-3479.

Fujita T et al. Once-weekly injection of low-dose teriparatide (28.2 μg) reduced the risk of vertebral fracture in

patients with primary osteoporosis. Calcif Tissue Int. 2014;94(2):170–175. doi:10.1007/s00223-013-9777-8.

van Staa TP et al. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int.

2002;13(10):777–787. doi:10.1007/s001980200108.

Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011;365(1):62–70.

doi:10.1056/NEJMcp1012926.

Grossman JM et al. American College of Rheumatology 2010 recommendations for the prevention and

treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515–1526.

doi:10.1002/acr.20295.

Saag KG et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis.

Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339(5):292–299.

doi:10.1056/NEJM199807303390502.

Adachi JD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients

receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum.

2001;44(1):202–211. doi:10.1002/1529-0131(200101)44:13.0.CO;2-W.

Stoch SA et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-

month randomized, placebo-controlled clinical trial. J Rheumatol. 2009;36(8):1705–1714.

doi:10.3899/jrheum.081207.

Cohen S et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter,

randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42(11):2309–2318.

doi:10.1002/1529-0131(199911)42:113.0.CO;2-K.

Reid DM et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced

osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet.

2009;373(9671):1253–1263. doi:10.1016/S0140-6736(09)60250-6.

Thomas T et al. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis

in clinical practice. Osteoporos Int. 2013;24(1):263–269. doi:10.1007/s00198-012-2060-4.

Saag KG et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirtysix-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346–3355.

doi:10.1002/art.24879.

Glüer C-C et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in

.

.

.

.

.

155.

.

.

.

.

.

.

.

.

.

.

men: 18-month results of the EuroGIOPs trial. J Bone Miner Res. 2013;28(6):1355–1368.

doi:10.1002/jbmr.1870.

Mok CC et al. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month

randomized controlled trial. Bone. 2015;75:222–228. doi:10.1016/j.bone.2015.03.002.

Petranova T et al. Denosumab improves bone mineral density and microarchitecture and reduces bone pain in

women with osteoporosis with and without glucocorticoid treatment. Biotechnol Biotechnol Equip.

2014;28(6):1127–1137. doi:10.1080/13102818.2014.967827.

Imaz I et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic

review and meta-analysis. Osteoporos Int. 2010;21(11):1943–1951. doi:10.1007/s00198-009-1134-4.

Mikyas Y et al. A systematic review of osteoporosis medication adherence and osteoporosis-related fracture

costs in men. Appl Health Econ Health Policy. 2014;12(3):267–277. doi:10.1007/s40258-013-0078-1.

Weiss TW et al. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy

prescription refills. Curr Med Res Opin. 2007;23(9):2193–2203. doi:10.1185/030079907X226069.

Briesacher BA et al. Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med.

2010;123(3):275–280. doi:10.1016/j.amjmed.2009.05.017.

Fan T et al. Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a

US pharmacy claims administrative database. Clin Outcomes Res CEOR. 2013;5:589–595.

doi:10.2147/CEOR.S39076.

Just for Men. National Osteoporosis Foundation. https://www.nof.org/preventing-fractures/generalfacts/just-for-men/. Accessed June 18, 2015.

Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab. 2010;95(1):3–10. doi:10.1210/jc.2009-1740.

Khosla S et al. Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab. 2002;87(4):1443–

1450. doi:10.1210/jcem.87.4.8417.

Kanis JA et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int.

2011;22(11):2789–2798. doi:10.1007/s00198-011-1632-z.

Orwoll E et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604–610.

doi:10.1056/NEJM200008313430902.

Boonen S et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled,

double-blind, multicenter study. J Bone Miner Res. 2009;24(4):719–725. doi:10.1359/jbmr.081214.

Orwoll ES et al. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly

70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, activecontrolled study. J Bone Miner Res. 2010;25(10):2239–2250. doi:10.1002/jbmr.119.

Orwoll ES et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men

with osteoporosis. J Bone Miner Res. 2003;18(1):9–17. doi:10.1359/jbmr.2003.18.1.9.

Schwarz P et al. The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a

systematic review and meta-analysis of antiresorptive and anabolic treatment in men. J Osteoporos.

2011;2011:1–9. doi:10.4061/2011/259818.

p. 2288

Note: Page number followed by f and t indicates figures and tables respectively

A

Abacavir (ABC), 58t, 1616

for HIV, 1577t

Abatacept, 881, 883, 896t, 897, 898, 904

Abciximab, 22

for ACS, 237

Abilify (see Aripiprazole)

Abiraterone, 2095, 2096

Abreva (see Docosanol cream)

Acamprosate, 1898–1899

Acarbose, for type 2 diabetes, 1125, 1126, 1134

ACE inhibitors (see Angiotensin-converting enzyme (ACE) inhibitors)

Acetaldehyde, 1892

Acetaminophen, 44, 49, 1182, 1183, 1185, 1187t, 1191, 1982t

analgesic syndrome from, 601

for arthritis, 2228

for burns, 863

for dysmenorrhea, 1015

for end-of-life care, 86

for HAV, 1665

hepatitis and, 1672

for migraine headache, 1237

neonates and, 2157, 2165, 2166

for OA, 867, 869

for PDA, 2181

PegIFN therapy, 1678

for postoperative pain management, 1180

pregnancy and, 79, 942t

toxicity with, 79–82

Acetazolamide, 564, 581

cryptococcal disease, 1643

and hypokalemia, 583t

Acid-related disorders, pharmacotherapy of drugs

antacids and alginic acid, 482, 484

bismuth salts, 486

H2

-receptor antagonists, 484

misoprostol, 486

PPI, 484–486

sucralfate, 486

Acitretin, for psoriasis, 836t, 840

Aclidinium bromide, for COPD, 420t

Acular (see Ketorolac)

Acupressure, 975

Acupuncture, 975

ACV (see Acyclovir (ACV))

Acyclovir (ACV), 744, 1648t, 1650

administration of, 1650

adverse effects of, 1334t, 1647, 1647t

dosing of, 1336t

for genital herpes, 1529, 1530t

for herpes encephalitis, 1646–1647

for herpes labialis, 1650–1651

for herpes simplex virus, 1167–1168, 1648, 1650

oral administration, 1647–1648

pharmacokinetics of, 1653t

for PHN, 1652, 1654

renal failure, dosing of drugs, 672–673

toxicity, 1654–1655

against varicella infection, 1652

Acyclovir and Hydrocortisone cream (Xerese), 1650

Acyclovir cream (Zovirax), 1650

ADACEL, 1357

Adalimumab, 881, 895, 896t, 904

for inflammatory bowel disease, 522t

for PsA, 842–843

for RA, 882

for UC, 527–528

Adapalene, 827, 828, 829, 830

Adefovir dipivoxil, 1678

Adenosine, 319–320

Ado-trastuzumab emtansine, 469t

Adrenaclick, 446t

Aerosolized aztreonam, 460

Afatinib, 470t

Aflibercept, 1169

Afrezza, 1084, 1086

Afrin (see Oxymetazoline)

Aggressive insulin therapy, 453

Akynzeo (see Palonosetron; Netupitant)

Alanine aminopeptidase, 1990

Albendazole, 1705t

for ascariasis, 1703t

for enterobiasis, 1703t

for filariasis, 1704t

for giardiasis, 1704t

for hookworm, 1704t

for hydatid cysts, 1705t

for pinworm, 1708

Albiglutide, 1126–1127

Albumin, 358

in edema, 573

Albuterol, 392, 689t

for acute asthma, 388

for AECOPD, 1408

anxiety from, 1736t

for chronic asthma, 395

fo

r

C

O

P

D

,

4

1

9

,

4

2

0

t

fo

r

e

n

d

-

o

flife

c

a

r

e

,

8

6

fo

r

hyp

e

r

ka

le

mia

,

5

8

7

t

w

ith

ip

r

a

tr

op

ium

,

8

6

mu

s

c

le

c

r

a

mp

s

a

n

d

,

1

7

2

t

n

e

b

uliz

a

t

io

n

,

3

8

9

,

5

8

6

r

e

s

p

ir

a

t

o

r

y

a

c

ido

s

is

a

n

d

,

5

6

5

A

l

c

a

ft

a

d

i

n

e

(

L

a

s

t

a

c

a

ft

)

,

4

3

9

t

,

1

1

6

5

A

l

c

o

h

o

l

,

1

6

2

7

a

n

d

a

c

ut

e

g

o

ut

,

9

1

5

A

F

a

n

d

,

3

1

2

t

fo

r

B

M

D

,

2

2

7

1

dia

b

e

t

e

s

a

n

d

,

1

0

8

1

GE

R

D

a

n

d

,

5

0

5

t

h

e

a

r

tb

ur

n

a

n

d

,

9

7

7

H

F

a

n

d

,

2

7

5

hyp

e

r

t

e

n

s

io

n

a

n

d

,

1

3

9

M

I

a

n

d

,

2

1

0

t

mu

s

c

le

c

r

a

mp

s

a

n

d

,

1

7

2

t

fo

r

o

s

t

e

op

o

r

o

s

is

,

2

2

7

4

p

ulmo

n

a

r

y

e

mb

o

lis

m

a

n

d

,

1

9

6–

1

9

7

fo

r

s

c

h

iz

op

hr

e

nia

,

1

7

8

3

t

t

e

r

a

t

o

g

e

nic

e

ffe

c

t

s

,

9

7

3

t

v

a

r

ia

nt

a

n

g

in

a

a

n

d

,

2

2

8

A

l

d

e

s

l

e

u

k

i

n

,

4

6

9

t

,

1

9

9

4

t

A

l

d

o

s

t

e

r

o

n

e

a

n

t

a

g

o

n

i

s

t

s

fo

r

A

C

S

,

2

3

8

t

fo

r

H

F

,

2

7

0

,

2

8

9

–

2

9

0

fo

r

hyp

e

r

t

e

n

s

io

n

,

1

4

0

,

1

4

8

–

1

4

9

t

,

1

5

7

in

le

ft

v

e

ntr

ic

ula

r

r

e

mo

d

e

lin

g

,

2

5

7

A

l

e

c

t

i

n

i

b

,

4

7

0

t

A

l

e

m

t

u

z

u

m

a

b

(

C

a

m

p

a

t

h

)

,

4

6

9

t

,

1

2

3

1

–

1

2

3

2

,

1

2

3

2

t

,

1

9

8

3

t

mo

n

o

c

lo

n

a

l

a

nt

ib

o

die

s

,

7

2

3

fo

r

M

S

,

1

2

2

2

A

l

e

n

d

r

o

n

a

t

e

,

2

2

7

7

–

2

2

7

8

,

2

2

7

7

t

a

n

dr

o

g

e

n

d

e

p

r

iv

a

t

io

n

th

e

r

a

p

y

,

2

0

9

7

do

s

e

,

2

2

7

9

fo

r

e

n

d

-

o

flife

c

a

r

e

,

8

6–

8

7

A

l

fe

n

t

a

n

i

l

,

2

1

3

1

t

A

l

fu

z

o

s

i

n

,

2

2

5

6

A

l

g

i

n

i

c

a

c

i

d

,

4

8

2

,

4

8

4

p. 2

2

8

9

p. 2

2

9

0

A

l

i

r

o

c

u

m

a

b

,

1

2

9

–

1

3

1

A

l

i

s

k

i

r

e

n

,

1

2

8

,

1

5

7

t

,

6

0

5

,

6

0

9

fo

r

hyp

e

r

t

e

n

s

io

n

,

1

4

0

,

1

5

8

A

l

l

e

g

r

a

(

s

e

e

F

e

x

o

fe

n

a

d

i

n

e

)

A

l

l

o

p

u

ri

n

o

l

,

5

8

t

,

9

1

6

,

9

1

7

t

fo

r

H

F

,

2

7

8

w

e

ight

g

a

in

w

ith

,

2

0

2

1

A

l

l

yl

a

m

i

n

e

s

,

1

6

2

4

,

1

6

2

5

A

l

m

o

t

ri

p

t

a

n

,

1

2

3

8

t

,

1

2

3

9

Alocril (see Nedocromil)

Alogliptin, 1127–1128

Alomide (see Lodoxamide)

Alosetron, 536

Aloxi (see Palonosetron)

α-adrenergic agonists, 503t

α-adrenergic blockers, 2242

α-blockers, 157–158

with β-blockers, 158–159

for hypertension, 140

Alphagan (see Brimonidine)

α2

-adrenergic agonist, 1878

α2

-agonists

for ADHD, 1870

for developmental disorders, 1855–1856

for hypertension, 159

Alprazolam (Xanax), 1027t, 1271t, 1272, 1737t, 1759

drug interaction with smoking, 1906t

for panic disorder, 1748

for PMDD, 1025

sedative-hypnotics, 1882

Alprostadil, 2266

Alrex (see Loteprednol)

Alteplase, for STEMI patients, 237

Altretamine, 470t

Aluminum hydroxide, 620t

Aluminum salts, 482, 917t

Amantadine (Symmetrel), 1224, 1250t, 1262, 1649t

adverse effects, 1647t

for Akathisia, 1800t

for influenza, 1655–1656

for Parkinsonism, 1799

pharmacokinetics of, 1653t

AmB (see Amphotericin B (AmB))

AmB formulation, 1643

Ambien, 1767t

Ambien CR, 1767t

Ambrisentan, 128, 924

Ameliorate, 1878

Amifostine, 469t, 1973–1974

Amikacin (Amikin), 461t, 1325t

adverse effects of, 1332t

for CAPD-associated peritonitis, 1476t

for CNS infections, 1373t

for gram-negative aerobes, 1327t

for MAC, 1619

pharmacodynamic actions of, 48

for tuberculosis, 1430t

for UTI, 1497t

Amikin (see Amikacin)

Amiloride, 543, 580–581

for hypertension, 148

Aminess, 794t

Aminobenzoates, 852

Aminoglycosides, 455, 460, 635–636, 1720

adverse effects of, 1332t

for CNS infections, 1373t

extended-interval dosing of, 461

for NEC, 2183

for neutropenic patients, 1563, 1564

for pneumonia, 1419

renal failure, dosing of drugs, 668–670

for RMSF, 1725

for sepsis, 2186

for UTI, 1497t

Aminopenicillin, 423

Aminophylline, 2189

Aminosalicylates

compounds, 523t

for inflammatory bowel disease, 520, 523

Aminosyn, 794t

Aminosyn HBC, 794t

Aminosyn II, 794t

Aminosyn-RF, 794t

Amiodarone, 120t, 214

for ACS, 238t

adverse effects of, 326

for AF, 316–317

antiadrenergic effects of, 326

for cardiopulmonary arrest, 331

for HF, 299–300

and liver toxicity, 326

and MI, 324

for SuVT, 324–325

for tachycardia, 1802

for ventricular arrhythmias treatment, 248

Amitriptyline, 535, 1181t, 1191, 1192, 1194t, 1242, 1245

for depressive disorders, 1819t, 1821t

Amlodipine, 120t, 155, 214

for chronic stable angina pectoris, 214

for vascular dementia, 2242

Ammonia, 822t

Amoxicillin (Amoxil), 493–494t, 496, 917t, 942t, 1326t, 1720, 2165

Amoxicillin/clavulanate

for CAPD-associated peritonitis, 1476t

for COPD, 418

and potassium clavulanate, 1488t

PPI and, 496–497

for skin and soft tissue infections, 1550

for UTI, 1488t

Amoxil (see Amoxicillin)

Amphetamine, 1885, 1868

for ADHD, 1867t

CNS stimulants, 1884

and lactation, 1003t

for schizophrenia, 1783, 1783t

Amphotericin

for CAPD-associated peritonitis, 1476t

and hypokalemia, 583t

nephrotoxicity by, 1400

Amphotericin B (AmB), 675, 1624, 1624t, 2009

5-FC and, 1400

adverse effects of, 1334t, 1632–1634

for aspergillosis, 1640–1641

candida infections

AmB-associated renal dysfunction, 1633

dose and duration of therapy, 1632

infusion-related reactions, 1632–1633

for cryptococcal meningitis, 1614–1615

dose and duration of therapy, 1629t, 1632

every-other-day regimens, 1632

formulations, 1635t

for histoplasmosis, 1637

intrathecal administration of, 1640

for leishmaniasis, 1705t

risk factor B, 1637

for sepsis, 2186t

Amphotericin B deoxycholate (AmBD), 1568

Ampicillin (Omnipen), 917t, 942t, 1326t, 2131t

for aerobic gram-positive cocci, 1326t

allergy, 684

for anaerobes, 1328t

for CAPD-associated peritonitis, 1476t

for chorioamnionitis, 996

for CNS infections, 1373t

dosing of, 1336t

for enterococcal endocarditis, 1397t

for gram-negative aerobes, 1327t

for NEC, 2183

for sepsis, 2186, 2186t

for UTI, 1488t, 1497t

Ampicillin-sulbactam

for CAPD-associated peritonitis, 1476t

for chorioamnionitis, 996

dosing of, 1336t

for UTI, 1497t

Amprenavir, 128, 942t

Amylase, and respiratory alkalosis, 1672

Amylin receptor agonists

adverse effects of, 1129

contraindications and precautions of, 1129

dosage and clinical use, 1129

drug interactions, 1129

efficacy of, 1129

mechanism of action, 1129

pharmacokinetics of, 1129

Anabolic steroids, for acne, 827

Anakinra, 881, 882–883, 896t, 903

Analgesics

for acute gout, 913

for burn pain, 863

drug interactions with, 1190t

for pain management, 1187t

for tension-type headache, 1245

Anastrozole, 1013

Ancef (see Cefazolin)

Androgen deprivation therapy (ADT), 2090

Androgen receptor antagonists for acne, 829

Androgens

for acne, 827

teratogenic effects, 973t

Anesthesia, 2107

Angiotensin-converting enzyme (ACE) inhibitors, 257, 694–695, 917t, 1207

for ACS, 238t

agents of choice, 279–282, 280f

angioedema and, 285, 695, 823

angiotensin receptor blockers and, 270–271, 282–284

p. 2290

p. 2291

CAD and, 147

CKD and, 146

cough and, 695

diabetes and, 146

in HFrEF, 281t

and hydralazine–isosorbide, 294–295

hyperkalemia and, 285

for hypertension, 139, 149t, 152–154

induced cough, 284–285

kidney function and, 285–286

left ventricular dysfunction and, 147

for PAD, 167

for patients with CKD, 617

for pregestational diabetes, 979

pregnancy and, 154

side effects of, 285–286

teratogenic effects, 973t

Angiotensin receptor blockers (ARBs), 213, 236, 267, 694–695, 984, 1207

for ACS, 238t

and angioedema, 285, 695

CAD and, 147

chronic kidney disease and, 147

diabetes and, 146

in HF, 282–284, 283t

for hyperkalemia, 285

for hypertension, 139–140, 149t, 154, 154t

and kidney function, 285–286

left ventricular dysfunction and, 147

side effects of, 285–286

Angiotensin receptor-neprilysin inhibitor (ARNI), 273

Anidulafungin, 1624t, 1625

adverse effects of, 1334t

Antacids, 482, 484, 713, 918t, 1974, 1975, 1976

for dyspepsia, 488

and fluoroquinolones, 41

for GER, 2162, 2163t

for GERD, 508

in preventing SRMB, 514, 515t

Anthracycline, 469t, 1981t, 1982t

Anthralin, for psoriasis, 835t, 837

Anthranilates, 849t, 852

Antiandrogen (see Spironolactone)

Antibiotics, 460, 524

for acne, 828

oral, 828

topical, 828

for acute bronchitis, 1406t

adverse effects of, 1332–1334t

for AECOPD, 1408–1409

for biliary infections, 1472–1473

in brain abscess, 1382

for Campylobacter infection, 1459

for CAP, 1412–1414

for CAPD-associated peritonitis, 1476t

for Chlamydia trachomatis, 927

for chorioamnionitis, 996

for chronic S. typhi carriers, 1456–1457

for CNS infections, 1373t

combination therapy, 1341

with corticosteroids, 819

costs of, 1335

CSF penetration characteristics of, 1371t

diarrhea from, 1463

dosing of, 460–462, 1335–1340, 1336–1339t

drug selection, 460

failure with, 1341–1342

for GBS infection, 995

for hospital-acquired pneumonia, 1417–1420

host factors and, 1342

for infectious diarrhea, 1449–1450

for Lyme disease, 1720

for nontyphoidalsalmonellosis, 1453

for nosocomial UTI, 1497t

pharmacokinetics/pharmacodynamics of, 1340–1341

pharmacologic factors, 1341–1342

for PPROM, 995

and protein binding, 1341

for pyelonephritis, 1495–1496

for relapsed UTI, 1498

resistance rates, 497

route of administration, 1335

for SARS, 1660

in SBP treatment, 1474

for shigellosis, 1457

STEC treatment and, 1463

for surgery, 1343–1349

for travelers’ diarrhea, 1459–1460

for typhoid fever, 1456

for UTI, 1486–1494

for V. cholerae infections, 1451

for V. parahaemolyticus gastroenteritis, 1452

Anticholinergics, 1261t

for asthma, 399

for COPD, 421–422

for end-of-life care, 89

GERD and, 503t

for Parkinson’s disease, 1258–1259

for schizophrenia, 1783, 1783t

Anticoagulants, 658, 917t

Anticonvulsants

for brain abscess, 1382–1383

for neuropathic pain, 1188

for PTSD, 1754

Antidepressants, 1778

for bipolar depression, 1847–1848

for patients with abdominal pain, 535–536

and sleep, 1773

toxicity from, 77

tricyclic (see Tricyclic antidepressants)

Antidiarrheals, 536

Antiemetics, 975, 976t, 1240

for CINV, 472–475, 472t

Antiepileptics

for critically ill patients, 1208

for depressive disorders, 1815t

for seizures, 1277t

Antiestrogen (Clomiphene citrate), 959, 1013

for polycystic ovary syndrome, 1012t

Antifungals

adverse effects of, 1334t

antifungalspectrum and susceptibility testing, 1625

for blastomycosis during pregnancy, 1637

cryptococcal disease, 1643

mechanism of action, 1624–1625

novel antifungal compounds, 1625–1626